BACKGROUND
The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is unclear. We used transcriptional and genomic profiling to define Burkitt's lymphoma more precisely and to distinguish subgroups in other types of mature aggressive B-cell lymphomas.
METHODS
We performed gene-expression profiling using Affymetrix U133A GeneChips with RNA from 220 mature aggressive B-cell lymphomas, including a core group of 8 Burkitt's lymphomas that met all World Health Organization (WHO) criteria. A molecular signature for Burkitt's lymphoma was generated, and chromosomal abnormalities were detected with interphase fluorescence in situ hybridization and array-based comparative genomic hybridization.
RESULTS
We used the molecular signature for Burkitt's lymphoma to identify 44 cases: 11 had the morphologic features of diffuse large-B-cell lymphomas, 4 were unclassifiable mature aggressive B-cell lymphomas, and 29 had a classic or atypical Burkitt's morphologic appearance. Also, five did not have a detectable IG-myc Burkitt's translocation, whereas the others contained an IG-myc fusion, mostly in simple karyotypes. Of the 176 lymphomas without the molecular signature for Burkitt's lymphoma, 155 were diffuse large-B-cell lymphomas. Of these 155 cases, 21 percent had a chromosomal breakpoint at the myc locus associated with complex chromosomal changes and an unfavorable clinical course.
CONCLUSIONS
Our molecular definition of Burkitt's lymphoma clarifies and extends the spectrum of the WHO criteria for Burkitt's lymphoma. In mature aggressive B-cell lymphomas without a gene signature for Burkitt's lymphoma, chromosomal breakpoints at the myc locus were associated with an adverse clinical outcome.
%0 Journal Article
%1 Hummel.2006
%A Hummel, Michael
%A Bentink, Stefan
%A Berger, Hilmar
%A Klapper, Wolfram
%A Wessendorf, Swen
%A Barth, Thomas F E,
%A Bernd, Heinz-Wolfram
%A Cogliatti, Sergio B.
%A Dierlamm, Judith
%A Feller, Alfred C.
%A Hansmann, Martin-Leo
%A Haralambieva, Eugenia
%A Harder, Lana
%A Hasenclever, Dirk
%A Kühn, Michael
%A Lenze, Dido
%A Lichter, Peter
%A Martin-Subero, Jose Ignacio
%A Möller, Peter
%A Müller-Hermelink, Hans-Konrad
%A Ott, German
%A Parwaresch, Reza M.
%A Pott, Christiane
%A Rosenwald, Andreas
%A Rosolowski, Maciej
%A Schwaenen, Carsten
%A Stürzenhofecker, Benjamin
%A Szczepanowski, Monika
%A Trautmann, Heiko
%A Wacker, Hans-Heinrich
%A Spang, Rainer
%A Loeffler, Markus
%A Trümper, Lorenz
%A Stein, Harald
%A Siebert, Reiner
%D 2006
%J The New England journal of medicine
%K IMISE-Publikationen
%N 23
%P 2419–2430
%T A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling
%V 354
%X BACKGROUND
The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is unclear. We used transcriptional and genomic profiling to define Burkitt's lymphoma more precisely and to distinguish subgroups in other types of mature aggressive B-cell lymphomas.
METHODS
We performed gene-expression profiling using Affymetrix U133A GeneChips with RNA from 220 mature aggressive B-cell lymphomas, including a core group of 8 Burkitt's lymphomas that met all World Health Organization (WHO) criteria. A molecular signature for Burkitt's lymphoma was generated, and chromosomal abnormalities were detected with interphase fluorescence in situ hybridization and array-based comparative genomic hybridization.
RESULTS
We used the molecular signature for Burkitt's lymphoma to identify 44 cases: 11 had the morphologic features of diffuse large-B-cell lymphomas, 4 were unclassifiable mature aggressive B-cell lymphomas, and 29 had a classic or atypical Burkitt's morphologic appearance. Also, five did not have a detectable IG-myc Burkitt's translocation, whereas the others contained an IG-myc fusion, mostly in simple karyotypes. Of the 176 lymphomas without the molecular signature for Burkitt's lymphoma, 155 were diffuse large-B-cell lymphomas. Of these 155 cases, 21 percent had a chromosomal breakpoint at the myc locus associated with complex chromosomal changes and an unfavorable clinical course.
CONCLUSIONS
Our molecular definition of Burkitt's lymphoma clarifies and extends the spectrum of the WHO criteria for Burkitt's lymphoma. In mature aggressive B-cell lymphomas without a gene signature for Burkitt's lymphoma, chromosomal breakpoints at the myc locus were associated with an adverse clinical outcome.
@article{Hummel.2006,
abstract = {BACKGROUND
The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is unclear. We used transcriptional and genomic profiling to define Burkitt's lymphoma more precisely and to distinguish subgroups in other types of mature aggressive B-cell lymphomas.
METHODS
We performed gene-expression profiling using Affymetrix U133A GeneChips with RNA from 220 mature aggressive B-cell lymphomas, including a core group of 8 Burkitt's lymphomas that met all World Health Organization (WHO) criteria. A molecular signature for Burkitt's lymphoma was generated, and chromosomal abnormalities were detected with interphase fluorescence in situ hybridization and array-based comparative genomic hybridization.
RESULTS
We used the molecular signature for Burkitt's lymphoma to identify 44 cases: 11 had the morphologic features of diffuse large-B-cell lymphomas, 4 were unclassifiable mature aggressive B-cell lymphomas, and 29 had a classic or atypical Burkitt's morphologic appearance. Also, five did not have a detectable IG-myc Burkitt's translocation, whereas the others contained an IG-myc fusion, mostly in simple karyotypes. Of the 176 lymphomas without the molecular signature for Burkitt's lymphoma, 155 were diffuse large-B-cell lymphomas. Of these 155 cases, 21 percent had a chromosomal breakpoint at the myc locus associated with complex chromosomal changes and an unfavorable clinical course.
CONCLUSIONS
Our molecular definition of Burkitt's lymphoma clarifies and extends the spectrum of the WHO criteria for Burkitt's lymphoma. In mature aggressive B-cell lymphomas without a gene signature for Burkitt's lymphoma, chromosomal breakpoints at the myc locus were associated with an adverse clinical outcome.},
added-at = {2014-10-15T15:03:57.000+0200},
author = {Hummel, Michael and Bentink, Stefan and Berger, Hilmar and Klapper, Wolfram and Wessendorf, Swen and {Barth, Thomas F E} and Bernd, Heinz-Wolfram and Cogliatti, Sergio B. and Dierlamm, Judith and Feller, Alfred C. and Hansmann, Martin-Leo and Haralambieva, Eugenia and Harder, Lana and Hasenclever, Dirk and Kühn, Michael and Lenze, Dido and Lichter, Peter and Martin-Subero, Jose Ignacio and Möller, Peter and Müller-Hermelink, Hans-Konrad and Ott, German and Parwaresch, Reza M. and Pott, Christiane and Rosenwald, Andreas and Rosolowski, Maciej and Schwaenen, Carsten and Stürzenhofecker, Benjamin and Szczepanowski, Monika and Trautmann, Heiko and Wacker, Hans-Heinrich and Spang, Rainer and Loeffler, Markus and Trümper, Lorenz and Stein, Harald and Siebert, Reiner},
biburl = {https://www.bibsonomy.org/bibtex/2e50217e43a00ecf41b96a86b387a1208/drtester},
interhash = {e98180fcb54a0e20cf9daa9616a03adb},
intrahash = {e50217e43a00ecf41b96a86b387a1208},
journal = {The New England journal of medicine},
keywords = {IMISE-Publikationen},
number = 23,
pages = {2419–2430},
timestamp = {2014-12-03T00:08:41.000+0100},
title = {A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling},
volume = 354,
year = 2006
}